Tags

Type your tag names separated by a space and hit enter

Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
J Clin Psychiatry. 2003 Nov; 64(11):1342-8.JC

Abstract

BACKGROUND

Risperidone has been reported to alleviate the severity of tardive dyskinesia, but without placebo control, the possibility of spontaneous tardive dyskinesia remission after discontinuing original conventional antipsychotics cannot be excluded. This 12-week randomized, double-blind, placebo-controlled study investigated the effect of risperidone on severe tardive dyskinesia.

METHOD

Forty-nine DSM-IV schizophrenia patients with severe tardive dyskinesia were enrolled in the study. After a 4-week washout period, the subjects were randomly assigned to treatment with either risperidone or placebo. The risperidone dose was started at 2 mg/day and gradually increased to 6 mg/day over 6 weeks; the 6-mg/day dose was maintained for the remaining 6 weeks of the study. The subjects were evaluated every 2 weeks with the Abnormal Involuntary Movement Scale (AIMS) and the Extrapyramidal Symptom Rating Scale. The final mental status was assessed with the Brief Psychiatric Rating Scale.

RESULTS

Twenty-two subjects in the risperidone group and 20 subjects in the placebo group completed the study; the mean baseline AIMS total score for all subjects was 15.9 +/- 4.6. At the end of the study, the mean AIMS total score decrease was 1.1 +/- 4.8 in the placebo group and 5.5 +/- 3.8 in the risperidone group (p <.05). Fifteen subjects (68%) in the risperidone group and 6 subjects (30%) in the placebo group were responders (p <.05). The risperidone responders had a mean AIMS total score decrease of 7.5 +/- 2.1. More significant tardive dyskinesia improvement among the risperidone group was noted from the eighth week and was mainly demonstrated in the buccolinguomasticatory a rea rather than in choreoathetoid movement of the extremities (p <.001).

CONCLUSIONS

Risperidone, 6 mg/day, can improve tardive dyskinesia more significantly than discontinuing antipsychotics in patients with severe tardive dyskinesia, especially in the orofacial areas.

Authors+Show Affiliations

Department of Psychiatry, Yu-Li Veterans Hospital, Hua-Lien, Taiwan. ymbi@ms1.hinet.netNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14658949

Citation

Bai, Ya-Mei, et al. "Risperidone for Severe Tardive Dyskinesia: a 12-week Randomized, Double-blind, Placebo-controlled Study." The Journal of Clinical Psychiatry, vol. 64, no. 11, 2003, pp. 1342-8.
Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(11):1342-8.
Bai, Y. M., Yu, S. C., & Lin, C. C. (2003). Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry, 64(11), 1342-8.
Bai YM, Yu SC, Lin CC. Risperidone for Severe Tardive Dyskinesia: a 12-week Randomized, Double-blind, Placebo-controlled Study. J Clin Psychiatry. 2003;64(11):1342-8. PubMed PMID: 14658949.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. AU - Bai,Ya-Mei, AU - Yu,Shun-Chieh, AU - Lin,Chao-Cheng, PY - 2003/12/9/pubmed PY - 2004/1/7/medline PY - 2003/12/9/entrez SP - 1342 EP - 8 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 64 IS - 11 N2 - BACKGROUND: Risperidone has been reported to alleviate the severity of tardive dyskinesia, but without placebo control, the possibility of spontaneous tardive dyskinesia remission after discontinuing original conventional antipsychotics cannot be excluded. This 12-week randomized, double-blind, placebo-controlled study investigated the effect of risperidone on severe tardive dyskinesia. METHOD: Forty-nine DSM-IV schizophrenia patients with severe tardive dyskinesia were enrolled in the study. After a 4-week washout period, the subjects were randomly assigned to treatment with either risperidone or placebo. The risperidone dose was started at 2 mg/day and gradually increased to 6 mg/day over 6 weeks; the 6-mg/day dose was maintained for the remaining 6 weeks of the study. The subjects were evaluated every 2 weeks with the Abnormal Involuntary Movement Scale (AIMS) and the Extrapyramidal Symptom Rating Scale. The final mental status was assessed with the Brief Psychiatric Rating Scale. RESULTS: Twenty-two subjects in the risperidone group and 20 subjects in the placebo group completed the study; the mean baseline AIMS total score for all subjects was 15.9 +/- 4.6. At the end of the study, the mean AIMS total score decrease was 1.1 +/- 4.8 in the placebo group and 5.5 +/- 3.8 in the risperidone group (p <.05). Fifteen subjects (68%) in the risperidone group and 6 subjects (30%) in the placebo group were responders (p <.05). The risperidone responders had a mean AIMS total score decrease of 7.5 +/- 2.1. More significant tardive dyskinesia improvement among the risperidone group was noted from the eighth week and was mainly demonstrated in the buccolinguomasticatory a rea rather than in choreoathetoid movement of the extremities (p <.001). CONCLUSIONS: Risperidone, 6 mg/day, can improve tardive dyskinesia more significantly than discontinuing antipsychotics in patients with severe tardive dyskinesia, especially in the orofacial areas. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/14658949/Risperidone_for_severe_tardive_dyskinesia:_a_12_week_randomized_double_blind_placebo_controlled_study_ L2 - http://www.psychiatrist.com/jcp/article/pages/2003/v64n11/v64n1110.aspx DB - PRIME DP - Unbound Medicine ER -